CHUN-JEN LIUJIA-HORNG KAODING-SHINN CHEN2021-09-042021-09-0420060016-5085https://www.scopus.com/inward/record.uri?eid=2-s2.0-33751214224&doi=10.1053%2fj.gastro.2006.10.005&partnerID=40&md5=de2cd240114a80226e23530981e313f3https://scholars.lib.ntu.edu.tw/handle/123456789/582200[SDGs]SDG3antineoplastic agent; cytotoxic agent; lamivudine; virus DNA; cancer chemotherapy; cancer patient; cost effectiveness analysis; hepatitis B; Hepatitis B virus; high risk population; human; immune deficiency; immune response; infection risk; kinetics; letter; priority journal; treatment outcome; virus reactivation; virus replicationletter10.1053/j.gastro.2006.10.005171013352-s2.0-33751214224